Researchers report pancreatic cancer breakthroughs in mRNA vaccines and KRAS-blocking trial
Updated
Updated · WKOW · Apr 30
Researchers report pancreatic cancer breakthroughs in mRNA vaccines and KRAS-blocking trial
12 articles · Updated · WKOW · Apr 30
UW Health oncologist Dr Jeremy Kratz said New York vaccine findings and the first phase two KRAS trial suggest some patients could live longer and improve early-stage cure chances.
He said the advances are especially important for borderline resectable cases, where combining chemotherapy with targeted drugs or immune-based treatments may stop spread and clear microscopic disease.
More than 67,000 Americans are expected to be diagnosed this year, and most are found late; Kratz said precision-medicine efforts in Wisconsin are helping match patients to more targeted, less toxic options.
Could the new mRNA vaccines and KRAS inhibitors finally turn the tide against pancreatic cancer, or are there hidden challenges that might slow progress?
With so many breakthroughs, how soon will patients outside major cancer centers actually benefit from these innovative therapies?
Breakthrough KRAS Inhibitor and Personalized mRNA Vaccine Transform Pancreatic Cancer Outcomes (2025–2026)
Overview
Recent advances in pancreatic cancer treatment highlight the success of daraxonrasib, a KRAS inhibitor that nearly doubled median survival to 13.2 months in a pivotal Phase 3 trial, driven by its unique mechanism blocking active KRAS signaling. Alongside, the personalized mRNA vaccine autogene cevumeran has shown remarkable long-term benefits, with responders achieving 87.5% survival over 4 to 6 years by inducing strong neoantigen-specific immune responses. While daraxonrasib is progressing toward FDA approval, the vaccine faces challenges due to high manufacturing costs and limited eligibility, as only about 20% of patients have operable tumors. Together, these therapies represent a promising shift toward precision and immunotherapy in pancreatic cancer care.